Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc. on March 11, 2021. Biota will retain a commercial license to apply the data science platform for genomic diagnostics. As part of Novozymes, the R&D team and data science platform will strengthen Novozymes’ ability to discover and deliver beneficial microbes to the world with unique and scientifically proven health and sustainability benefits. The addition of Biota’s R&D team and data science platform will give Novozymes a technical edge for pursuing new opportunities and further strengthen existing solutions in OneHealth, Novozymes’ human health unit. Furthermore, the acquisition will act as a foundational enabler for many of its key industries, including Animal Health, BioAg and Household Care. Novozymes A/S (CPSE:NZYM B) completed the acquisition of the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc. on March 11, 2021.